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Oo the Editor: Transcatheter aortic valve implantation (TAVI) has
merged as a promising alternative to surgical aortic valve replace-
ent for patients with severe aortic stenosis considered to be at
igh operative risk. TAVI is most commonly performed via the
emoral artery. However, the large-diameter delivery catheters of
oth the Edwards Sapien (Edwards Lifesciences, Irvine, Califor-
ia) and Medtronic CoreValve (Medtronic Inc., Minneapolis,
innesota) systems preclude a transfemoral approach in a signif-
cant number of patients. The Sapien valve can be delivered using
transapical technique, but this is a more invasive procedure, and
nitial observational data suggest that outcomes are worse (1,2). A
ubclavian approach has been reported as a viable alternative for
he CoreValve (3). However, there are limited data describing
utcomes with this technique.
We analyzed a consecutive cohort of 288 patients implanted at
centers in the United Kingdom and Ireland between April 2007
nd April 2010 to determine the characteristics and outcomes of
atients undergoing CoreValve TAVI via a subclavian approach,
ompared with those treated transfemorally. Data were obtained
y retrospective analysis of case notes and institutional databases.
rincipal outcome measures were procedural success, valve posi-
ion, major vascular complications, and the 30-day incidence of
eath, stroke, and major adverse cardiovascular and cerebrovascular
vents (MACCE). Major vascular complications included retro-
eritoneal hemorrhage, limb ischemia, and any complication
equiring percutaneous or surgical intervention. MACCE con-
isted of death, myocardial infarction, stroke, conversion to sur-
ery, emergent percutaneous coronary intervention, cardiogenic
hock, endocarditis, repeat valvular intervention, cardiac tampon-
de, and aortic dissection or rupture (4). Categorical variables were
ompared using the Fisher exact test and continuous variables
sing 2-tailed unpaired t tests for comparisons between groups and
aired t tests for intragroup comparisons. Analyses were performed
sing Stata software (StataCorp LP, College Station, Texas).
The procedure was performed using a transfemoral approach in
53 patients (88.2%) and via the subclavian artery in 35 (11.8%).
emographics, procedural data, and 30-day outcomes are shown
n Table 1. Logistic EuroSCORE (European System for Cardiac
perative Risk Evaluation) scores were significantly higher in the
ubclavian cohort, as was the incidence of peripheral vascular
isease, carotid artery disease, previous myocardial infarction,
hronic obstructive pulmonary disease, and impaired left ventric-
lar function.
Valve position was more frequently reported as “optimal” in the
ubclavian group. Major vascular complications were numerically
ore frequent in the femoral cohort, but blood transfusion was
ore common in the subclavian patients. Thirty-day mortality was
% in subclavian patients versus 4.7% in femoral patients (p 
c
c.30). MACCE at 30 days showed a trend toward reduced events
n the subclavian cohort (2.9% vs. 13.4%, p  0.09).
Currently available TAVI systems require relatively large,
ealthy vessels for conventional transfemoral access. The Edwards
apien valve has until recently been delivered via a 22- or 24-F
atheter, precluding a femoral approach in up to 50% of patients.
ajor access site complications have been a significant source of
orbidity and mortality, with an incidence of 10.6% in the largest
eported Edwards transfemoral registry (1). The CoreValve is
elivered via a smaller 18-F catheter, but a significant minority of
atients remain unsuitable for femoral access.
The design of the Edwards valve permits a transapical approach
n patients without suitable peripheral vessels. However, this
rocedure is more invasive, and early studies indicate that out-
omes are worse, with significantly higher mortality both at 30
ays and at 12 months, albeit in patients with higher EuroSCORE
1,2). A transapical technique is not routinely available with the
oreValve device. However, alternative vascular access is possible
sing the subclavian artery, which is less frequently affected by
theromatous disease and in most patients can accommodate an
8-F sheath.
omparison Between Subclavian and Transfemoral TAVITable 1 Comparison Between Subclavian and Transfemoral TAVI
Variable
Transfemoral Subclavian
p Value(n  253) (n  35)
Baseline characteristics
Age (yrs) 81.7 6.4 80.6 4.9 0.33
Logistic EuroSCORE (%) 19.1 12.3 25.0 14.7 0.02
Coronary artery disease 148 (58.5%) 26 (74.2%) 0.09
Previous MI 41 (16.2%) 12 (34.3%) 0.02
Previous PCI 61 (24.1%) 12 (34.3%) 0.22
Carotid artery disease 15 (5.9%) 6 (17.1%) 0.03
Peripheral vascular disease 54 (21.3%) 26 (74.2%) 0.0001
COPD 47 (18.6%) 14 (40.0%) 0.007
LVEF 50% 94 (37.2%) 23 (65.7%) 0.004
Procedural results
Procedural success 246 (97.2%) 35 (100%) 1.00
“Optimal” valve position 153 (60.5%) 31 (88.6%) 0.001
Major vascular complications 25 (9.9%) 1 (2.9%) 0.34
Blood transfusion 47 (18.6%) 13 (37.1%) 0.02
30-day outcomes
Mortality 12 (4.7%) 0 (0%) 0.37
Stroke 11 (4.3%) 1 (2.9%) 0.86
MACCE 34 (13.4%) 1 (2.9%) 0.09
ata are expressed as mean  SD or n (%).
COPD  chronic obstructive pulmonary disease; EuroSCORE  European System for Cardiac
perative Risk Evaluation; LVEF  left ventricular ejection fraction; MACCE  major adverse
ardiovascular and cerebrovascular events; MI  myocardial infarction; PCI  percutaneous
oronary intervention; TAVI  transcatheter aortic valve implantation.
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635JACC Vol. 57, No. 5, 2011 Correspondence
February 1, 2011:634–6In common with transapical series, we found that subclavian
atients were a higher risk cohort than transfemoral patients, with
ignificantly higher average EuroSCORE, more prevalent comor-
idities, and more frequent impairment of left ventricular function.
owever, in contrast to major transapical registries, outcomes of
ubclavian TAVI were at least as good as in the transfemoral
ohort, with 100% procedural success, 0% mortality at 30 days, and
strong trend toward reduced MACCE. The more frequent
ttainment of an “optimal” valve position in the subclavian cohort
ay reflect greater control of the deployment catheter, because the
istance and tortuosity between the access site and valve are
educed.
One other national multicenter experience of 54 subclavian
oreValve TAVI cases has recently been reported, with very
imilar findings (3). Subclavian patients had significantly higher
uroSCORE and an increased incidence of peripheral vascular
isease, coronary artery disease, prior myocardial infarction, and
rior percutaneous coronary intervention than femoral patients.
he 30-day mortality was 0% versus 6.1% in the femoral cohort
p  0.13). “Suboptimal” valve positions were more frequently
bserved in femoral patients.
The findings of this study are limited by the relatively small
umber of subclavian patients, the registry design, and the absence
f independent event adjudication. Nonetheless, the U.K. experi-
nce is consistent with existing data in demonstrating excellent
utcomes with a subclavian approach in patients without suitable
emoral access despite a higher risk profile, supporting the use of
his technique for CoreValve TAVI in these patients. This
ontrasts with reported outcomes of transapical TAVI and raises
he possibility that the subclavian approach may be preferable to
ransapical access in patients with peripheral vascular disease.
We conclude that TAVI via the subclavian artery is a safe and
easible alternative in patients without suitable femoral access.
nouska M. Moynagh, MB
. Julian A. Scott, MD
ndreas Baumbach, MD
li Khavandi, MB
tephen J. Brecker, MD
ean-Claude Laborde, MD
een similar with no major complications in a series of 103 Fidelis
e
r
l
r
m
i
c
l
p
n
i
gue Brown, BSc
aqib Chowdhary, PhD
uraisamy Saravanan, MB
eter A. Crean, MD
inead Teehan, BNS
avid Hildick-Smith, MD
day Trivedi, MD
aib S. Khogali, MD
oninder S. Bhabra, DM
avid H. Roberts, MD
enneth P. Morgan, MB
Daniel J. Blackman, MD
or the UK CoreValve Collaborative
Department of Cardiology
eeds General Infirmary
reat George Street
eeds, LS1 3EX
nited Kingdom
-mail: daniel.blackman@leedsth.nhs.uk
doi:10.1016/j.jacc.2010.08.642
lease note: Drs. Blackman, Brecker, and Hildick-Smith are proctors for Medtronic
oreValve. Dr. Laborde is a consultant for Medtronic CoreValve.
EFERENCES
. Thomas M, Schymik G, Walther T, et al. Thirty-day results of the
SAPIEN Aortic Bioprosthesis European Outcome (SOURCE) regis-
try: European registry of transcatheter aortic valve implantation using
the Edwards SAPIEN valve. Circulation 2010;122:62–9.
. Schächinger V, Lefevre T, de Bruyne B, et al. Results from the
PARTNER EU trial: Prospective Multicentric European Registry of
Transcatheter Aortic Valve Implantation. Paper presented at: EuroPCR;
May 19–22, 2009; Barcelona, Spain.
. Petronio AS, De Carlo M, Bedogni F, et al. Safety and efficacy of the
subclavian approach for transcatheter aortic valve implantation with the
CoreValve ReValving System. Circ Cardiovasc Interv 2010;3:359–66.
. Grube E, Schuler G, Buellesfeld L, et al. Percutaneous aortic valve
replacement for severe aortic stenosis in high-risk patients using the
second- and current third-generation self-expanding CoreValve pros-
thesis: device success and 30-day clinical outcome. J Am Coll Cardiol
2007;50:69–76.Letters to the Editorulticenter Experience
ith Extraction of the
print Fidelis Implantable
ardioverter-Defibrillator Lead
e read with interest the recent multicenter report of the safe
xtraction experience with the Sprint Fidelis lead (Medtronic,
inneapolis, Minnesota) (1). Our single-center experience hasxtractions. We agree with the authors that the time has come to
econsider the recommendations for Fidelis lead management in
ight of this and other data. In addition to the established
elationship between shock frequency and mortality (2), the
orbidity of lead failure in these patients is severe and psycholog-
cally long-lasting, often leading to significant disability (3); this,
oupled with the recently reported exponential increase in Fidelis
ead failures over time, suggests that routine advice at the time of
ulse generator replacement should now be to electively remove all
ormally functioning Fidelis leads (4). Because the risk of system
nfection is assumed by opening the pocket to replace the pulse
enerator, there is essentially no additional risk except that related
